Literature DB >> 11168014

Poor immune reconstitution after four or five major HLA antigens mismatched T cell-depleted allogeneic and autologous stem cell transplantation.

J Mattsson1, M Uzunel, M Remberger, L Tammik, B Omazic, V Levitsky, J Z Zou, P Hentschke, O Ringdén.   

Abstract

Two adults with primary liver cancer underwent liver transplantation from 5/6 and 4/6 major HLA-antigen mismatched unrelated donors. They were then conditioned with 4 x 2 Gy of total lymphoid irradiation, 120 mg/kg cyclophosphamide, 7.5 Gy total body irradiation and anti-T cell antibodies. Thereafter, the patients received T cell-depleted autologous: unrelated mismatched bone marrow in a proportion of 0.5:3.0 and 0.35:1.1 x 10(6) CD34+ cells/kg, respectively. After allogeneic stem cell transplantation (ASCT), both became mixed chimeras, as determined with polymerase chain reaction amplification of variable number tandem repeats from DNA obtained from CD3+, CD19+ and CD45+ magnetic bead-separated cells. Due to a reduction in donor T cells, the first patient was given 10(5) donor T cells/kg and became a complete donor chimera within 3 months. The second patient rejected all donor cells within 1 month after ASCT. Leucocytes normalized in both patients within 1 month. CD8+ cells normalized after 4 and 2 months in the two patients, respectively. However, CD4+, CD56+ and CD19+ cells remained low, except for a transient increase in patient 2. Lymphocyte responses to mitogens were negative in patient 1 from 1 to 5 months after ASCT. This patient also showed an oligoclonal pattern of the B cell repertoire, performed by CDR3 spectratyping. Epstein-Barr virus DNA in lymphocytes increased by 4-5 log in both patients. Prior to ASCT, recipients and donors were mutually reactive in mixed lymphocyte cultures (MLC). In the first patient, who became a complete donor chimera, the chimera cells showed no response to recipient or donor, but a positive response to third party. In the other patient, recipient cells reacted vigorously against donor lymphocytes at the time of rejection. Both patients suffered from overwhelming bacterial, fungal and viral infections, and died of pneumonia 5 and 3 months after ASCT, respectively. To conclude, with a major HLA-mismatch barrier, stable mixed chimerism seems difficult to achieve. The first patient became a full donor chimera and the second one rejected the graft. Both suffered from immune incompetence.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11168014      PMCID: PMC1905954          DOI: 10.1046/j.1365-2249.2001.01429.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  40 in total

1.  Role of MLC compatibility in intrafamilial kidney transplantation.

Authors:  O Ringdén; E Möller; G Lundgren; C G Groth
Journal:  Transplantation       Date:  1976-07       Impact factor: 4.939

Review 2.  Bone-marrow transplantation (first of two parts).

Authors:  E Thomas; R Storb; R A Clift; A Fefer; F L Johnson; P E Neiman; K G Lerner; H Glucksberg; C D Buckner
Journal:  N Engl J Med       Date:  1975-04-17       Impact factor: 91.245

3.  Does graft-versus-host disease influence the tempo of immunologic recovery after allogeneic human marrow transplantation? An observation on 56 long-term survivors.

Authors:  D R Noel; R P Witherspoon; R Storb; K Atkinson; K Doney; E M Mickelson; H D Ochs; R P Warren; P L Weiden; E D Thomas
Journal:  Blood       Date:  1978-06       Impact factor: 22.113

4.  Activation of human B and T lymphocytes by protein A of Staphylococcus aureus.

Authors:  O Ringdén
Journal:  Eur J Immunol       Date:  1978-01       Impact factor: 5.532

5.  Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia.

Authors:  H Zetterquist; J Mattsson; M Uzunel; I Näsman-Björk; P Svenberg; L Tammik; G Bayat; J Winiarski; O Ringdén
Journal:  Bone Marrow Transplant       Date:  2000-04       Impact factor: 5.483

6.  Transplantation of autologous and allogeneic bone marrow with liver from a cadaveric donor for primary liver cancer.

Authors:  O Ringdén; G Söderdahl; J Mattsson; M Uzunel; M Remberger; P Hentschke; H Hägglund; E Sparrelid; A Elmhorn-Rosenborg; F Duraj; H Zetterquist; B G Ericzon
Journal:  Transplantation       Date:  2000-05-27       Impact factor: 4.939

7.  Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system.

Authors:  R M Zinkernagel; P C Doherty
Journal:  Nature       Date:  1974-04-19       Impact factor: 49.962

8.  Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease.

Authors:  J Mattsson; M Uzunel; M Remberger; P Ljungman; E Kimby; O Ringdén; H Zetterquist
Journal:  Leukemia       Date:  2000-02       Impact factor: 11.528

Review 9.  Mixed chimerism: preclinical studies and clinical applications.

Authors:  P A McSweeney; R Storb
Journal:  Biol Blood Marrow Transplant       Date:  1999       Impact factor: 5.742

10.  Long-term persistence of oligoclonal serum IgM repertoires in patients treated with allogeneic bone marrow transplantation (BMT).

Authors:  I N Björk; C Brissac; M Remberger; J Mattsson; S Klaesson; O Ringdén; J Stewart; I Lundkvist
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.